DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company

Monthly information regarding the total number of voting rights and total number of shares of the Company

     Monthly information regarding the total number of voting rights and 

total number of shares of the Company

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
12/31/201947,028,510 



Total gross of voting rights: 47,028,510



 
 



Total net* of voting rights:  47,019,510



 

* Total net = total number of voting rights attached to shares – shares without voting rights

Attachment

EN
14/01/2020

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and total num...

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024                                                                                                                                                                                                                                                                                                                  Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Au...

April 4, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date  Nombre totald’actionscomposant le capital socialNombre totalde droits de vote31/03/2024 96 434 369  Total brut des droits de vote : 96 434 369  Total net* des droits de vote : 96 171 725  *Total net = nombre total de dro...

April 4, 2024 1 EN
Free Trial
DBV DBV Technologie...

DBV Technologies SA: 1 director

A director at DBV Technologies SA bought 34,188 shares at 0.861USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

DBV DBV TECHNOLOGIES SA
03/13/24 March 13, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies announces filing of 2023 Annual Report on Form 10-K a...

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on F...

March 8, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies publie son « Form 10-K » américain et son Document d’...

DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2023 Montrouge, France, le 8 mars 2024 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2023 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique au stade clinique (la « Société »), a annoncé aujourd'hui que son « Form 10-K » 2023 avait été déposé auprès de la Securities and Exchange Commission (« SEC ») aux Etats-Unis ainsi que son document d’enregistrement universel 2023 (« DEU »), auprès de l’Autor...

March 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch